Science | Nature | Cell | View More
Natural Products
Roflumilast
Roflumilast
ChemFaces products have been cited in many studies from excellent and top scientific journals
Product Name Roflumilast
Price:
CAS No.: 162401-32-3
Catalog No.: CFN90020
Molecular Formula: C17H14Cl2F2N2O3
Molecular Weight: 403.21 g/mol
Purity: >=98%
Type of Compound: Miscellaneous
Physical Desc.: Powder
Source:
Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Download: COA    MSDS    SDF
Similar structural: Comparison (Web)  (SDF)
Guestbook:
Contact Us
Order & Inquiry & Tech Support

Tel: (0086)-27-84237683
Tech: service@chemfaces.com
Order: manager@chemfaces.com
Address: 176, CheCheng Eest Rd., WETDZ, Wuhan, Hubei 430056, PRC
How to Order
Orders via your E-mail:

1. Product number / Name / CAS No.
2. Delivery address
3. Ordering/billing address
4. Contact information
Order: manager@chemfaces.com
Delivery time
Delivery & Payment method

1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

2. We accept: Wire transfer & Credit card & Paypal
Citing Use of our Products
* Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
According to end customer requirements, ChemFaces provide solvent format. This solvent format of product intended use: Signaling Inhibitors, Biological activities or Pharmacological activities.
Size /Price /Stock 10 mM * 1 mL in DMSO / Inquiry
Other Packaging *Packaging according to customer requirements(100uL/well, 200uL/well and more), and Container use Storage Tube With Screw Cap
Our products had been exported to the following research institutions and universities, And still growing.
  • Medical University of Gdansk (Poland)
  • Universidad de Ciencias y Artes... (Mexico)
  • Utrecht University (Netherlands)
  • University of the Basque Country (Spain)
  • CSIRO - Agriculture Flagship (Australia)
  • Kyung Hee University (Korea)
  • Kyoto University (Japan)
  • Universiti Kebangsaan Malaysia (Malaysia)
  • Kazusa DNA Research Institute (Japan)
  • Shanghai Institute of Biochemis... (China)
  • Rio de Janeiro State University (Brazil)
  • More...
Package
Featured Products
Epimedin B

Catalog No: CFN99940
CAS No: 110623-73-9
Price: $128/20mg
Cryptochlorogenic acid

Catalog No: CFN99117
CAS No: 905-99-7
Price: $90/20mg
Kaempferol 3,7-di-O-glucoside

Catalog No: CFN91159
CAS No: 25615-14-9
Price: $288/5mg
Sauchinone

Catalog No: CFN90153
CAS No: 177931-17-8
Price: $60/20mg
Ardisiacrispin A

Catalog No: CFN90177
CAS No: 23643-61-0
Price: $268/5mg
Demethylsuberosin

Catalog No: CFN96241
CAS No: 21422-04-8
Price: $188/20mg
Kaempferol-3-O-(2',6'-di-O-trans-p...

Catalog No: CFN92386
CAS No: 121651-61-4
Price: $ / mg
(2-Acetoxyethyl)trimethylammonium

Catalog No: CFN00011
CAS No: 51-84-3
Price: $ /
Platycodin D

Catalog No: CFN98134
CAS No: 58479-68-8
Price: $70/20mg
Angustifoline

Catalog No: CFN92233
CAS No: 550-43-6
Price: $490/5mg
Related Screening Libraries
Size /Price /Stock 10 mM * 100 uL in DMSO / Inquiry / In-stock
10 mM * 1 mL in DMSO / Inquiry / In-stock
Related Libraries
Biological Activity
Description: Roflumilast is a phosphodiesterase 4 inhibitor that may improve lung function and reduce the frequency of exacerbations in patients with COPD. Roflumilast has anti-inflammatory and immunomodulatory potential,it will be useful in the treatment of chronic inflammatory disorders such as asthma and chronic obstructive pulmonary disease. Suppression of hematological and immunological markers of inflammation and enhanced apoptosis in animals treated with Roflumilast points to the possibility of a beneficial effect of Roflumilast in allergic inflammation.
Targets: cAMP | ROS | IL Receptor | PDE
In vitro:
Am J Physiol Lung Cell Mol Physiol. 2015 May 15;308(10):L1068-77.
Roflumilast combined with adenosine increases mucosal hydration in human airway epithelial cultures after cigarette smoke exposure.[Pubmed: 25795727]
Chronic obstructive pulmonary disease (COPD) is a growing cause of morbidity and mortality worldwide. Recent studies have shown that cigarette smoke (CS) induces cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction, which leads to airway-surface liquid (ASL) dehydration. This in turn contributes to the mucus dehydration and impaired mucociliary clearance that are seen in the chronic bronchitis form of COPD. Roflumilast is a phosphodiesterase 4 inhibitor that may improve lung function and reduce the frequency of exacerbations in patients with COPD. Although Roflumilast can affect cAMP metabolism, little is known about the downstream pharmacological effects in the airways.
METHODS AND RESULTS:
We hypothesized that Roflumilast would increase ASL rehydration in human bronchial epithelial cultures (HBECs) after chronic CS exposure. cAMP production was measured by Förster resonance energy transfer in HEK293T cells and by ELISA in HBECs. ASL height was measured by xz-confocal microscopy after air exposure or following HBEC exposure to freshly produced CS. Roflumilast had little effect on cAMP or ASL height when applied on its own; however, Roflumilast significantly potentiated adenosine-induced increases in cAMP and ASL height in CS-exposed HBECs. Roflumilast increased the rate of ASL height recovery in cultures after CS exposure compared with controls. In contrast, the β2-adrenergic receptor agonists isoproterenol and salmeterol failed to increase ASL height after CS exposure.
CONCLUSIONS:
Our data suggest that Roflumilast can increase ASL hydration in CS-exposed HBECs, which is predicted to be beneficial for the treatment of mucus dehydration/mucus stasis in patients with COPD chronic bronchitis.
J Pharmacol Exp Ther. 2001 Apr;297(1):267-79.
Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.[Pubmed: 11259554]

METHODS AND RESULTS:
From a series of benzamide derivatives, Roflumilast (3-cyclo-propylmethoxy-4-difluoromethoxy-N-[3,5-di-chloropyrid-4-yl]-benzamide) was identified as a potent and selective PDE4 inhibitor. It inhibits PDE4 activity from human neutrophils with an IC(50) of 0.8 nM without affecting PDE1 (bovine brain), PDE2 (rat heart), and PDE3 and PDE5 (human platelets) even at 10,000-fold higher concentrations. Roflumilast is almost equipotent to its major metabolite formed in vivo (Roflumilast N-oxide) and piclamilast (RP 73401), however, more than 100-fold more potent than rolipram and Ariflo (cilomilast; SB 207499). The anti-inflammatory and immunomodulatory potential of Roflumilast and the reference compounds was investigated in various human leukocytes using cell-specific responses: neutrophils [N-formyl-methyl-leucyl-phenylalanine (fMLP)-induced formation of LTB(4) and reactive oxygen species (ROS)], eosinophils (fMLP- and C5a-induced ROS formation), monocytes, monocyte-derived macrophages, and dendritic cells (lipopolysaccharide-induced tumor necrosis factor-alpha synthesis), and CD4+ T cells (anti-CD3/anti-CD28 monoclonal antibody-stimulated proliferation, IL-2, IL-4, IL-5, and interferon-gamma release). Independent of the cell type and the response investigated, the corresponding IC values (for half-maximum inhibition) of Roflumilast were within a narrow range (2-21 nM), very similar to Roflumilast N-oxide (3-40 nM) and piclamilast (2-13 nM). In contrast, cilomilast (40-3000 nM) and rolipram (10-600 nM) showed greater differences with the highest potency for neutrophils. Compared with neutrophils and eosinophils, representing the terminal inflammatory effector cells, the relative potency of Roflumilast and its N-oxide for monocytes, CD4+ T cells, and dendritic cells is substantially higher compared with cilomilast and rolipram, probably reflecting an improved immunomodulatory potential.
CONCLUSIONS:
The efficacy of Roflumilast in vitro and in vivo (see accompanying article in this issue) suggests that Roflumilast will be useful in the treatment of chronic inflammatory disorders such as asthma and chronic obstructive pulmonary disease.
In vivo:
Toxicol Pathol. 2015 Jun;43(4):569-80.
Roflumilast-induced Local Vascular Injury Is Associated with a Coordinated Proteome and Microparticle Change in the Systemic Circulation in Pigs.[Pubmed: 25311372]
Drug-induced vascular injury (DIVI) is commonly associated with phosphodiesterase (PDE) inhibitors. Despite histological characterization, qualified biomarkers for DIVI detection are lacking.
METHODS AND RESULTS:
We investigated whether a single administration of Roflumilast (PDE-IV inhibitor) induces vascular damage and identified novel surrogate biomarkers of acute vascular injury. Pigs received postoperative 250, 375, or 500 μg of Roflumilast or placebo/control. After 1.5 hr, coronary reactivity was determined by catheter-based administration of acetylcholine and sodium nitroprusside (SNP) in the coronary sinus. Immunohistochemical analysis of vessel integrity (von Willebrand factor [vWF]) and fibrin(ogen) deposition was performed in the coronary artery and aorta. Peripheral blood was collected for differential proteomics and microparticles analysis. Circulating interleukin (IL)-6 was analyzed. Roflumilast-treated animals displayed higher vasodilation to acetylcholine and SNP versus controls (p < .05). Roflumilast-treated animals showed a dose-dependent (p < .05) decrease in vessel integrity and dose-dependent increase in fibrin deposition forming a continuous layer at Roflumilast-500 μg. Peripheral blood of Roflumilast-500-μg-treated animals showed increased levels of total and endothelial-derived microparticles and exhibited a coordinated change in proteins kininogen-1, endothelin-1, gelsolin, apolipoprotein A-I, and apolipoprotein-J associated with vascular injury (p < .05 vs. controls). IL-6 remained unaltered.
CONCLUSIONS:
Roflumilast-induced vascular injury can be detected by novel markers in peripheral blood. Validation of these surrogate markers in human samples seems required.
Roflumilast Description
Source:
Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
ChemFaces New Products and Compounds
Maculosidin

Catalog No: CFN95126
CAS No: 522-19-0
Price: $413/5mg
3'-O-Methylviolanone

Catalog No: CFN95387
CAS No: 56973-42-3
Price: $318/5mg
1,2-Epoxy-10(14)-furanogermacren-6...

Catalog No: CFN95214
CAS No: 383368-24-9
Price: $318/10mg
Foliachinenoside C

Catalog No: CFN95361
CAS No: 1041180-87-3
Price: $368/5mg
6-O-(E)-Caffeoylglucopyranose

Catalog No: CFN95105
CAS No: 209797-79-5
Price: $298/5mg
Decursitin D

Catalog No: CFN95002
CAS No: 245446-61-1
Price: $388/5mg
3',4',5',5,7-Pentamethoxyflavanone

Catalog No: CFN95414
CAS No: 479672-30-5
Price: $218/20mg
15-Methoxy-16-oxo-15,16H-strictic ...

Catalog No: CFN95261
CAS No: 1356388-38-9
Price: $368/5mg
Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

Cell. 2018 Jan 11;172(1-2):249-261.e12.
doi: 10.1016/j.cell.2017.12.019.
IF=36.216(2019)

PMID: 29328914

Cell Metab. 2020 Mar 3;31(3):534-548.e5.
doi: 10.1016/j.cmet.2020.01.002.
IF=22.415(2019)

PMID: 32004475

Mol Cell. 2017 Nov 16;68(4):673-685.e6.
doi: 10.1016/j.molcel.2017.10.022.
IF=14.548(2019)

PMID: 29149595

ACS Nano. 2018 Apr 24;12(4): 3385-3396.
doi: 10.1021/acsnano.7b08969.
IF=13.903(2019)

PMID: 29553709

Nature Plants. 2016 Dec 22;3: 16206.
doi: 10.1038/nplants.2016.205.
IF=13.297(2019)

PMID: 28005066

Sci Adv. 2018 Oct 24;4(10): eaat6994.
doi: 10.1126/sciadv.aat6994.
IF=12.804(2019)

PMID: 30417089
Calculate Dilution Ratios(Only for Reference)
1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.4801 mL 12.4005 mL 24.801 mL 49.6019 mL 62.0024 mL
5 mM 0.496 mL 2.4801 mL 4.9602 mL 9.9204 mL 12.4005 mL
10 mM 0.248 mL 1.24 mL 2.4801 mL 4.9602 mL 6.2002 mL
50 mM 0.0496 mL 0.248 mL 0.496 mL 0.992 mL 1.24 mL
100 mM 0.0248 mL 0.124 mL 0.248 mL 0.496 mL 0.62 mL
* Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
Protocol
Animal Research:
Adv Exp Med Biol. 2015;838:11-8.
Influence of roflumilast on airway reactivity and apoptosis in ovalbumin-sensitized Guinea pigs.[Pubmed: 25310957]
Chronic inflammatory diseases, associated with airway obstruction and cough, are usually treated with bronchodilating and anti-inflammatory drugs. Inhibition of phosphodiesterases (PDE) leads to both of these effects and influences apoptosis of immune cells. In chronic obstructive pulmonary disease, Roflumilast, a selective PDE4 inhibitor, has been recently approved for pharmacotherapy.
METHODS AND RESULTS:
The aim of this study was to evaluate the effect of long-term administration of Roflumilast in experimental allergic inflammation in guinea pigs. Male adult guinea pigs were used in the study. There were four experimental groups sensitized with ovalbumin for 14 days and thereafter treated per os, by inhalation, and intraperitoneally for 7 days with Roflumilast or vehicle. A control group was left without sensitization. Roflumilast reduced specific airway resistance after nebulization of histamine, as measured in a double-chamber whole-body plethysmograph. This effect was confirmed in in vitro organ bath, with significant decreases in tracheal and lung smooth muscle contractility after cumulative doses of histamine.
CONCLUSIONS:
Suppression of hematological and immunological markers of inflammation and enhanced apoptosis in animals treated with Roflumilast points to the possibility of a beneficial effect of Roflumilast in allergic inflammation.
Epimedin B

Catalog No: CFN99940
CAS No: 110623-73-9
Price: $128/20mg
Cryptochlorogenic acid

Catalog No: CFN99117
CAS No: 905-99-7
Price: $90/20mg
Kaempferol 3,7-di-O-glucoside

Catalog No: CFN91159
CAS No: 25615-14-9
Price: $288/5mg
Sauchinone

Catalog No: CFN90153
CAS No: 177931-17-8
Price: $60/20mg
Ardisiacrispin A

Catalog No: CFN90177
CAS No: 23643-61-0
Price: $268/5mg
Demethylsuberosin

Catalog No: CFN96241
CAS No: 21422-04-8
Price: $188/20mg
Kaempferol-3-O-(2',6'-di-O-trans-p...

Catalog No: CFN92386
CAS No: 121651-61-4
Price: $ / mg
(2-Acetoxyethyl)trimethylammonium

Catalog No: CFN00011
CAS No: 51-84-3
Price: $ /
Platycodin D

Catalog No: CFN98134
CAS No: 58479-68-8
Price: $70/20mg
Angustifoline

Catalog No: CFN92233
CAS No: 550-43-6
Price: $490/5mg
Tags: buy Roflumilast | Roflumilast supplier | purchase Roflumilast | Roflumilast cost | Roflumilast manufacturer | order Roflumilast | Roflumilast distributor